Insight Molecular Diagnostics Inc. (IMDX) — Cash Flow-to-Debt Ratio
Insight Molecular Diagnostics Inc. (IMDX) has a Cash Flow-to-Debt Ratio of -0.15x as of March 2026, meaning its operating cash flow of $-7.64 Million could theoretically repay 0% of its total liabilities ($51.12 Million) in one year. Check IMDX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Insight Molecular Diagnostics Inc. Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Insight Molecular Diagnostics Inc. across 13 annual periods. Also explore Insight Molecular Diagnostics Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Insight Molecular Diagnostics Inc. (2013–2025)
Year-by-year debt coverage analysis for Insight Molecular Diagnostics Inc.. For market capitalisation and broader financial context, see IMDX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.39x | $-22.18 Million | $57.22 Million | ▲ +11.4% |
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▼ -2.1% |
| 2023 | -0.43x | $-23.32 Million | $54.42 Million | ▲ +43.1% |
| 2022 | -0.75x | $-45.57 Million | $60.50 Million | ▼ -97.7% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |